Eli Lilly Q1 2025 Earnings: Mounjaro, Zepbound Push Revenue to Record $12.7 Billion Amid Strong Pipeline Momentum

Eli Lilly and Company (NYSE: LLY) delivered a blockbuster first quarter for fiscal 2025, fueled by the surging success of its diabetes and obesity treatments—Mounjaro and Zepbound—and further bolstered by…

Continue ReadingEli Lilly Q1 2025 Earnings: Mounjaro, Zepbound Push Revenue to Record $12.7 Billion Amid Strong Pipeline Momentum

Why Invo Fertility (IVF) is Up Over 100% Today: Revenue Explosion, Strategic Refocus, and Fertility Market Tailwinds

Invo Fertility Inc. (NASDAQ: IVF) grabbed headlines on April 30, 2025, after its stock price doubled intraday—rallying from a prior close of $1.61 to a high of $3.20. This remarkable…

Continue ReadingWhy Invo Fertility (IVF) is Up Over 100% Today: Revenue Explosion, Strategic Refocus, and Fertility Market Tailwinds